title: [Fluoxetine (FX) efficacy in the treatment of cocaine dependence methadone maintenance patients. Interaction with plasma levels].
abstract: OBJECTIVE
  The objective of this study was to assess the efficacy of fluoxetine (FX) treatment in cocaine dependent methadone (MTD) maintenance patients, to assess decrease or interruption of cocaine use and pharmacokinetic interaction between fluoxetine an methadone plasma levels.
  
  
  METHODS
  The sample was composed of 11 patients with DSM IV criteria for opioid and cocaine dependence. We added Fluoxetine (20 mg per day) during 9 weeks in Majadahonda Drug Program. All patients were in methadone program a mean of 7.5 months. We made a psychiatry interview and the baseline severity of the mood disorder was assessed with the Clinical Global Impression ICG for therapeutic improvement. Cocaine use and fluoxetine treatment was measured in urine analysis and pharmacokinetic interaction between FX-MTD were measured with plasma levels of methadone.
  
  
  RESULTS
  Fluoxetine was well tolerated combined with methadone. FX-MTD interaction didn't occur, resulting in no increased of MTD plasma level to dose before and after fluoxetine treatment. After fluoxetine treatment decreased cocaine use, changed cocaine tract from injected to smoked and improvement depressive symptoms.
authors.affiliation: Programa Municipal de Drogas, Majadahonda, Madrid, 28220, España.
authors.forename: M D
authors.initials: MD
authors.lastname: Baño
authors.forename: M
authors.initials: M
authors.lastname: Agujetas
authors.forename: M L
authors.initials: ML
authors.lastname: López
authors.forename: T
authors.initials: T
authors.lastname: Tena
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez
authors.forename: C
authors.initials: C
authors.lastname: Lora-Tamayo
authors.forename: J L
authors.initials: JL
authors.lastname: Guillén
mesh_terms: D000328:Adult; D019970:Cocaine-Related Disorders / Q000534:rehabilitation*; D004347:Drug Interactions; D005260:Female; D005473:Fluoxetine / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008691:Methadone / Q000627:therapeutic use*; D009294:Narcotics / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005473:Fluoxetine; D008691:Methadone; D009294:Narcotics; D017367:Selective Serotonin Reuptake Inhibitors